A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Macquarie University, Sydney

Westmead, Westmead

ICON Cancer Centre, Auchenflower

Cancer Research South Australia, Adelaide

Montefiore Medical Center, The Bronx

Winship Cancer Institute of Emory University, Atlanta

Advent Health, Orlando

University of Miami, Sylvester Comprehensive Cancer Center, Deerfield Beach

Florida Cancer Center, Sarasota

Sarah Cannon Research Institute, Nashville

Ohio State University Comprehensive Cancer Center, Columbus

Cleveland Clinic Taussig Cancer Center, Cleveland

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

Saint Luke's Hospital of Kansas City, Kansas City

University of Colorado, Aurora

UCLA Hematology/Oncology, Los Angeles

Providence Portland Medical Center, Portland

OHSU Knight Cancer Institute, Portland

Dana Farber Cancer Institute, Boston